PCSA
Processa Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$2.22-3.90%
Price as of Jul 20, 2026
PCSA financials
Processa Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $874.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | -$874.0K |
| Operating expenses | $14.0M | $12.1M | $11.5M | $19.4M |
| Operating income | -$14.0M | -$12.1M | -$11.5M | -$20.3M |
| Net income | -$13.6M | -$11.9M | -$11.1M | -$27.4M |
| EBITDA | -$13.6M | -$11.8M | -$11.1M | -$26.6M |
| Basic EPS | $-10.36 | $-96.75 | $-212.00 | $-851.19 |
| Diluted EPS | $-10.36 | $-96.75 | $-212.00 | $-851.19 |
| Balance sheet | ||||
| Cash & equivalents | $5.5M | $1.2M | $4.7M | $6.5M |
| Total assets | $7.8M | $3.2M | $5.8M | $8.6M |
| Total liabilities | $2.2M | $1.5M | $797.5K | $1.1M |
| Stockholders’ equity | $5.6M | $1.7M | $5.0M | $7.5M |
| Total debt | $0.00 | $73.5K | $150.6K | $229.4K |
| Net debt | -$5.5M | -$1.1M | -$4.6M | -$6.3M |
| Cash flow | ||||
| Operating cash flow | -$11.4M | -$11.2M | -$8.1M | -$9.6M |
| Capital expenditure | -$5.00 | -$3.2K | -$2.8K | $3.00 |
| Free cash flow | -$11.4M | -$11.2M | -$8.1M | -$9.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | -$15.9K | $0.00 | -$388.8K |